OncoMatch/Clinical Trials/NCT06158828
Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML
Is NCT06158828 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments for aml, childhood.
Treatment: Rabbit Anti thymocyte globulin · Busulfan · Fludarabine · Thiotepa · Melphalan · TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graft · memory-like natural killer cells · IL-2 · Plerixafor · Granulocyte Colony-Stimulating Factor · CliniMACS — This trial represents a single institution phase I/II pilot study with the primary objective of establishing the safety and feasibility of generating and infusing ML NK cells after TCRαβ haplo-HCT.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: RPN1 RPN1-MECOM
RPN1-MECOM
Required: RUNX1 RUNX1-MECOM
RUNX1-MECOM
Required: NPM1 NPM1-MLF1
NPM1-MLF1
Required: DEK DEK-NUP214
DEK-NUP214
Required: KAT6A KAT6A-CREBBP
KAT6A-CREBBP (if ≥ 90 days at diagnosis)
Required: FUS FUS-ERG
FUS-ERG
Required: KMT2A (MLL) KMT2A-AFF1
KMT2A-AFF1
Required: KMT2A (MLL) KMT2A-AFDN
KMT2A-AFDN
Required: KMT2A (MLL) KMT2A-ABI1
KMT2A-ABI1
Required: KMT2A (MLL) KMT2A-MLLT1
KMT2A-MLLT1
Required: NUP98 rearrangement (any partner gene)
11p15 rearrangement (NUP98 - any partner gene)
Required: ETV6 rearrangement (any partner gene)
12p13.2 rearrangement (ETV6 - any partner gene)
Required: ETV6 deletion (loss of ETV6)
Deletion 12p to include 12p13.2 (loss of ETV6)
Required: EGR1 deletion (loss of EGR1)
Monosomy 5/Del(5q) to include 5q31 (loss of EGR1)
Required: FLT3 ITD with allelic ratio > 0.1%, without bZIP CEBPA or NPM1
FLT3/ITD with allelic ratio > 0.1%, without bZIP CEBPA or NPM1
Demographics
Prior therapy
Must have received: hematopoietic cell transplant
One prior hematopoietic cell transplant is allowed, provided remission criteria as defined above are met.
Lab requirements
Kidney function
GFR ≥ 60 mL/min/1.73m2 or serum creatinine < 2 x IULN for age/gender
Liver function
Total bilirubin ≤ 3 x IULN for age; AST(SGOT)/ALT(SGPT) ≤ 5 x IULN for age
Cardiac function
LVEF at rest ≥50% or shortening fraction (SF) ≥27% (via echocardiogram or MUGA)
Adequate organ function as defined below: Total bilirubin ≤ 3 x IULN for age; AST(SGOT)/ALT(SGPT) ≤ 5 x IULN for age; GFR ≥ 60 mL/min/1.73m2...serum creatinine < 2 x IULN for age/gender. Adequate cardiac function, defined by LVEF at rest ≥50% or SF ≥27%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Washington University School of Medicine · St Louis, Missouri
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06158828 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received hematopoietic cell transplant.
Does this trial require RPN1?
Yes, RPN1 RPN1-MECOM is a required biomarker for enrollment.
Does this trial require RUNX1?
Yes, RUNX1 RUNX1-MECOM is a required biomarker for enrollment.
Does this trial require NPM1?
Yes, NPM1 NPM1-MLF1 is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 40 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify